Varicella zoster virus reactivation reported with isatuximab use
- PMID: 37800850
- DOI: 10.1080/1120009X.2023.2266201
Varicella zoster virus reactivation reported with isatuximab use
Abstract
Isatuximab is a CD38-directed antibody indicated for the treatment of relapsed or refractory multiple myeloma. The Division of Pharmacovigilance at the U.S. Food and Drug Administration (FDA) reviewed case reports from postmarketing sources, including the FDA Adverse Event Reporting System (FAERS), PubMed, and Embase, to investigate a potential association between isatuximab and the risk of varicella zoster virus (VZV) reactivation. We identified 20 reports of which 15 met our case definition and causality criteria. All 15 patients (80% male, median age = 60 years) received isatuximab for a hematologic neoplasm; eight (53%) for previously untreated multiple myeloma. All cases described additional risk factors for VZV reactivation, including concomitant proteasome inhibitor and/or immunomodulatory drug (n = 10, 67%) use. Based on this postmarket analysis, the U.S. Prescribing Information for isatuximab was updated to include this new safety information, including recommendations for antiviral prophylaxis.
Keywords: CD38-directed therapies; Isatuximab; multiple myeloma; varicella zoster virus reactivation.
Similar articles
-
Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis.Int J Clin Pharm. 2023 Dec;45(6):1492-1495. doi: 10.1007/s11096-023-01608-7. Epub 2023 Jun 8. Int J Clin Pharm. 2023. PMID: 37289318
-
Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.J Support Oncol. 2012 Jul-Aug;10(4):155-9. doi: 10.1016/j.suponc.2011.10.006. Epub 2012 Jan 4. J Support Oncol. 2012. PMID: 22222250
-
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.Ann Hematol. 2014 Mar;93(3):479-84. doi: 10.1007/s00277-013-1951-6. Epub 2013 Dec 7. Ann Hematol. 2014. PMID: 24318541
-
Isatuximab for the treatment of relapsed/refractory multiple myeloma.Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404. doi: 10.1080/14712598.2021.1841747. Expert Opin Biol Ther. 2020. PMID: 33111607 Review.
-
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.Semin Oncol. 2020 Apr-Jun;47(2-3):155-164. doi: 10.1053/j.seminoncol.2020.04.004. Epub 2020 May 8. Semin Oncol. 2020. PMID: 32446599 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
